These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22855094)

  • 1. Education becomes focus of classwide opioid REMS.
    Thompson CA
    Am J Health Syst Pharm; 2012 Aug; 69(16):1352. PubMed ID: 22855094
    [No Abstract]   [Full Text] [Related]  

  • 2. Advisers say FDA's opioid REMS program needs improvement.
    Traynor K
    Am J Health Syst Pharm; 2016 Jul; 73(13):940-2. PubMed ID: 27325870
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on medication guides.
    Park LM; Jones PR; Pearsall BM; Araojo RT
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):129-132. PubMed ID: 29280228
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
    Matthews ML
    J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Providers need to boost efforts to prevent abuse of narcotics.
    Reinke T
    Manag Care; 2014 Apr; 23(4):11-2. PubMed ID: 24868600
    [No Abstract]   [Full Text] [Related]  

  • 10. Blueprint for prescriber continuing education program.
    Center For Drug Evaluation And Research Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for the upcoming FDA REMS proposal.
    Peppin JF; Coleman JJ; Kirsh KL
    J Opioid Manag; 2011; 7(3):173-6. PubMed ID: 21823548
    [No Abstract]   [Full Text] [Related]  

  • 12. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA asks Purdue Pharma to withdraw Palladone.
    FDA Consum; 2005; 39(5):7. PubMed ID: 16419284
    [No Abstract]   [Full Text] [Related]  

  • 14. New Warnings for Opioid Analgesics.
    Aschenbrenner DS
    Am J Nurs; 2016 Jul; 116(7):25. PubMed ID: 27336987
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA opioid safety plan promotes patient, physician education to prevent abuse.
    Kuehn BM
    JAMA; 2010 Aug; 304(8):845. PubMed ID: 20736462
    [No Abstract]   [Full Text] [Related]  

  • 16. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food and Drug Administration labeling and medication guides: A health outcomes critique.
    Watterson TL
    Res Social Adm Pharm; 2019 Sep; 15(9):1191-1192. PubMed ID: 31003764
    [No Abstract]   [Full Text] [Related]  

  • 19. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 20. Don't overlook directions.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Dec; 96(12):14-5. PubMed ID: 8961854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.